MedTrace Logo

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

NCT00065429 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2012-07-18

Study results available
· View outcomes & findings →

Summary

This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.

Conditions

Interventions

DRUG

BB-10901

I.V. Infusion - See "Arms" for dosage - Once/Week for three weeks - Until Progression of disease.

Sponsors & Collaborators

  • ImmunoGen, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2008-11-30
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00065429 on ClinicalTrials.gov